Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care

M. Balik, P. Waldauf, I. Jurisinova, E. Svobodova, M. Diblickova, T. Tencer, J. Zavora, G. Smela, L. Kupidlovska, V. Adamkova, M. Fridrichova, K. Jerabkova, J. Mikes, F. Duska, L. Dusek

. 2024 ; 14 (1) : 20825. [pub] 20240906

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018976

Grantová podpora
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky
AZV NU22-B-147 Agentura Pro Zdravotnický Výzkum České Republiky

Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19. The viral load was estimated by detecting nucleocapsid antigen in serum (n = 155, median 217(28;1524)pg/ml), antigen in sputum (n = 18, COI 18(4.6;32)), nasopharyngeal antigen (n = 44, COI 17(8;35)) and the real-time PCR (n = 122, Ct 21(18;27)). After adjustment for confounders, patients on remdesivir had better 12-month survival (HR 0.66 (0.44;0.98), p = 0.039), particularly when admitted to the ICU (HR 0.49 (0.29;0.81), p = 0.006). For the immunocompromised patients, the difference did not reach statistical significance (HR 0.55 (0.18;1.69), p = 0.3). The other most significant confounders were age, ICU admission, mechanical ventilation, leukocyte/lymphocyte ratio, admission creatinine and immunosuppression. The impact of monoclonal antibodies or previous vaccinations was not significant. Despite frequent immune suppression including haemato-oncology diseases, lymphopenia, and higher inflammatory markers in the remdesivir group, the results support remdesivir administration with respect to widely available estimates of viral load in patients with high illness severity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018976
003      
CZ-PrNML
005      
20241024111205.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-024-71588-9 $2 doi
035    __
$a (PubMed)39242658
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Balik, M $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic. martin.balik@vfn.cz $1 https://orcid.org/0000000318642143 $7 xx0075661
245    10
$a SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care / $c M. Balik, P. Waldauf, I. Jurisinova, E. Svobodova, M. Diblickova, T. Tencer, J. Zavora, G. Smela, L. Kupidlovska, V. Adamkova, M. Fridrichova, K. Jerabkova, J. Mikes, F. Duska, L. Dusek
520    9_
$a Remdesivir therapy has been declared as efficient in the early stages of Covid-19. Of the 339 patients (males 55.8%, age 71(59;77) years) with a detectable viral load, 140 were treated with remdesivir (of those 103 in the ICU and 57 immunosuppressed) and retrospectively compared with 199 patients (of those 82 in the ICU and 28 immunosuppressed) who were denied therapy due to advanced Covid-19. The viral load was estimated by detecting nucleocapsid antigen in serum (n = 155, median 217(28;1524)pg/ml), antigen in sputum (n = 18, COI 18(4.6;32)), nasopharyngeal antigen (n = 44, COI 17(8;35)) and the real-time PCR (n = 122, Ct 21(18;27)). After adjustment for confounders, patients on remdesivir had better 12-month survival (HR 0.66 (0.44;0.98), p = 0.039), particularly when admitted to the ICU (HR 0.49 (0.29;0.81), p = 0.006). For the immunocompromised patients, the difference did not reach statistical significance (HR 0.55 (0.18;1.69), p = 0.3). The other most significant confounders were age, ICU admission, mechanical ventilation, leukocyte/lymphocyte ratio, admission creatinine and immunosuppression. The impact of monoclonal antibodies or previous vaccinations was not significant. Despite frequent immune suppression including haemato-oncology diseases, lymphopenia, and higher inflammatory markers in the remdesivir group, the results support remdesivir administration with respect to widely available estimates of viral load in patients with high illness severity.
650    _2
$a lidé $7 D006801
650    12
$a adenosinmonofosfát $x analogy a deriváty $x terapeutické užití $7 D000249
650    12
$a alanin $x analogy a deriváty $x terapeutické užití $7 D000409
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a virová nálož $x účinky léků $7 D019562
650    _2
$a senioři $7 D000368
650    12
$a SARS-CoV-2 $x účinky léků $x izolace a purifikace $x fyziologie $7 D000086402
650    _2
$a lidé středního věku $7 D008875
650    12
$a farmakoterapie COVID-19 $7 D000093485
650    12
$a COVID-19 $x virologie $x mortalita $7 D000086382
650    12
$a antivirové látky $x terapeutické užití $7 D000998
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a péče o pacienty v kritickém stavu $7 D003422
650    _2
$a jednotky intenzivní péče $7 D007362
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
700    1_
$a Waldauf, P $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
700    1_
$a Jurisinova, I $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic
700    1_
$a Svobodova, E $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic
700    1_
$a Diblickova, M $u Department of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 2, Prague 2, Prague, 12800, Czech Republic
700    1_
$a Tencer, T $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
700    1_
$a Zavora, J $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic $u Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Smela, G $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
700    1_
$a Kupidlovska, L $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
700    1_
$a Adamkova, V $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, and General University Hospital, Prague, Czech Republic
700    1_
$a Fridrichova, M $u Department of Laboratory Diagnostics, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
700    1_
$a Jerabkova, K $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
700    1_
$a Mikes, J $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
700    1_
$a Duska, F $u Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital in Prague, Prague, Czech Republic
700    1_
$a Dusek, L $u Faculty of Medicine, Institute of Health Information and Statistics of the Czech Republic, Masaryk University, Brno, Czech Republic
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 14, č. 1 (2024), s. 20825
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39242658 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111159 $b ABA008
999    __
$a ok $b bmc $g 2201675 $s 1230949
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 1 $d 20825 $e 20240906 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a AZV NU22-B-147 $p Agentura Pro Zdravotnický Výzkum České Republiky
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...